| Miss Farrah Kaiss Alahmady, AA | |
|
12221 N Mopac Expy, Austin, TX 78758-2401 | |
| (512) 901-1000 | |
| Not Available |
| Full Name | Miss Farrah Kaiss Alahmady |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology Assistant |
| Experience | 6 Years |
| Location | 12221 N Mopac Expy, Austin, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083198014 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | AA471 (Florida) | Secondary |
| 367H00000X | Anesthesiologist Assistant | 27111431 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Luxe Anesthesia Pllc | 1355652991 | 7 |
News Archive
A report from the Organization for Economic Cooperation and Development (OECD) released on Tuesday, found that "Asia-Pacific countries have seen steady gains in key health indicators since 1970, but developing nations there are still far behind standards in the industrialised world," Deutsche Presse-Agentur/M&C reports. OECD looked at "[h]ealth systems for 27 Asia-Pacific economies," according to the news service (12/21).
Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today reported results for its fourth quarter and full year ended December 31, 2011. Full financial statements and corresponding commentary can be found in the Company's Form 10-K, which will be filed with the Securities and Exchange Commission on March 30, 2012.
Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell, subject to customary closing conditions, $4.06 million of securities to an accredited investor in a private offering pursuant to Section 4(2) of the Securities Act of 1933, as amended. The securities consist of 4,060 shares of Series 6 preferred stock, no par value per share, together with warrants to purchase an aggregate of 5.8 million shares of common stock (the "Series 6 Financing"). The offering is scheduled to close on or about July 27, 2010, subject to the satisfaction of customary closing conditions.
pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has submitted a Marketing Authorization Application (MAA) to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK) for Iluvien®.
What if there were a way to make chemotherapy and radiation more effective as cancer treatments than they are today, while also getting rid of debilitating side effects that patients dread? A new study led by Alexey Ryazanov, a professor of pharmacology at Rutgers Robert Wood Johnson Medical School and member of the Rutgers Cancer Institute of New Jersey, suggests the day that happens could be getting closer.
› Verified 5 days ago
| Entity Name | Austin Anesthesiology Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598724304 PECOS PAC ID: 0547256497 Enrollment ID: O20040424000086 |
News Archive
A report from the Organization for Economic Cooperation and Development (OECD) released on Tuesday, found that "Asia-Pacific countries have seen steady gains in key health indicators since 1970, but developing nations there are still far behind standards in the industrialised world," Deutsche Presse-Agentur/M&C reports. OECD looked at "[h]ealth systems for 27 Asia-Pacific economies," according to the news service (12/21).
Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today reported results for its fourth quarter and full year ended December 31, 2011. Full financial statements and corresponding commentary can be found in the Company's Form 10-K, which will be filed with the Securities and Exchange Commission on March 30, 2012.
Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell, subject to customary closing conditions, $4.06 million of securities to an accredited investor in a private offering pursuant to Section 4(2) of the Securities Act of 1933, as amended. The securities consist of 4,060 shares of Series 6 preferred stock, no par value per share, together with warrants to purchase an aggregate of 5.8 million shares of common stock (the "Series 6 Financing"). The offering is scheduled to close on or about July 27, 2010, subject to the satisfaction of customary closing conditions.
pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has submitted a Marketing Authorization Application (MAA) to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK) for Iluvien®.
What if there were a way to make chemotherapy and radiation more effective as cancer treatments than they are today, while also getting rid of debilitating side effects that patients dread? A new study led by Alexey Ryazanov, a professor of pharmacology at Rutgers Robert Wood Johnson Medical School and member of the Rutgers Cancer Institute of New Jersey, suggests the day that happens could be getting closer.
› Verified 5 days ago
| Entity Name | Luxe Anesthesia Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588042899 PECOS PAC ID: 1355652991 Enrollment ID: O20150623001552 |
News Archive
A report from the Organization for Economic Cooperation and Development (OECD) released on Tuesday, found that "Asia-Pacific countries have seen steady gains in key health indicators since 1970, but developing nations there are still far behind standards in the industrialised world," Deutsche Presse-Agentur/M&C reports. OECD looked at "[h]ealth systems for 27 Asia-Pacific economies," according to the news service (12/21).
Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today reported results for its fourth quarter and full year ended December 31, 2011. Full financial statements and corresponding commentary can be found in the Company's Form 10-K, which will be filed with the Securities and Exchange Commission on March 30, 2012.
Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell, subject to customary closing conditions, $4.06 million of securities to an accredited investor in a private offering pursuant to Section 4(2) of the Securities Act of 1933, as amended. The securities consist of 4,060 shares of Series 6 preferred stock, no par value per share, together with warrants to purchase an aggregate of 5.8 million shares of common stock (the "Series 6 Financing"). The offering is scheduled to close on or about July 27, 2010, subject to the satisfaction of customary closing conditions.
pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has submitted a Marketing Authorization Application (MAA) to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK) for Iluvien®.
What if there were a way to make chemotherapy and radiation more effective as cancer treatments than they are today, while also getting rid of debilitating side effects that patients dread? A new study led by Alexey Ryazanov, a professor of pharmacology at Rutgers Robert Wood Johnson Medical School and member of the Rutgers Cancer Institute of New Jersey, suggests the day that happens could be getting closer.
› Verified 5 days ago
| Entity Name | Texas Anesthesia Partners, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144673468 PECOS PAC ID: 3870879828 Enrollment ID: O20170406000406 |
News Archive
A report from the Organization for Economic Cooperation and Development (OECD) released on Tuesday, found that "Asia-Pacific countries have seen steady gains in key health indicators since 1970, but developing nations there are still far behind standards in the industrialised world," Deutsche Presse-Agentur/M&C reports. OECD looked at "[h]ealth systems for 27 Asia-Pacific economies," according to the news service (12/21).
Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today reported results for its fourth quarter and full year ended December 31, 2011. Full financial statements and corresponding commentary can be found in the Company's Form 10-K, which will be filed with the Securities and Exchange Commission on March 30, 2012.
Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell, subject to customary closing conditions, $4.06 million of securities to an accredited investor in a private offering pursuant to Section 4(2) of the Securities Act of 1933, as amended. The securities consist of 4,060 shares of Series 6 preferred stock, no par value per share, together with warrants to purchase an aggregate of 5.8 million shares of common stock (the "Series 6 Financing"). The offering is scheduled to close on or about July 27, 2010, subject to the satisfaction of customary closing conditions.
pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has submitted a Marketing Authorization Application (MAA) to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK) for Iluvien®.
What if there were a way to make chemotherapy and radiation more effective as cancer treatments than they are today, while also getting rid of debilitating side effects that patients dread? A new study led by Alexey Ryazanov, a professor of pharmacology at Rutgers Robert Wood Johnson Medical School and member of the Rutgers Cancer Institute of New Jersey, suggests the day that happens could be getting closer.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Miss Farrah Kaiss Alahmady, AA 919 E 32nd St, Austin, TX 78705-2703 Ph: (469) 939-9969 | Miss Farrah Kaiss Alahmady, AA 12221 N Mopac Expy, Austin, TX 78758-2401 Ph: (512) 901-1000 |
News Archive
A report from the Organization for Economic Cooperation and Development (OECD) released on Tuesday, found that "Asia-Pacific countries have seen steady gains in key health indicators since 1970, but developing nations there are still far behind standards in the industrialised world," Deutsche Presse-Agentur/M&C reports. OECD looked at "[h]ealth systems for 27 Asia-Pacific economies," according to the news service (12/21).
Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today reported results for its fourth quarter and full year ended December 31, 2011. Full financial statements and corresponding commentary can be found in the Company's Form 10-K, which will be filed with the Securities and Exchange Commission on March 30, 2012.
Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell, subject to customary closing conditions, $4.06 million of securities to an accredited investor in a private offering pursuant to Section 4(2) of the Securities Act of 1933, as amended. The securities consist of 4,060 shares of Series 6 preferred stock, no par value per share, together with warrants to purchase an aggregate of 5.8 million shares of common stock (the "Series 6 Financing"). The offering is scheduled to close on or about July 27, 2010, subject to the satisfaction of customary closing conditions.
pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has submitted a Marketing Authorization Application (MAA) to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK) for Iluvien®.
What if there were a way to make chemotherapy and radiation more effective as cancer treatments than they are today, while also getting rid of debilitating side effects that patients dread? A new study led by Alexey Ryazanov, a professor of pharmacology at Rutgers Robert Wood Johnson Medical School and member of the Rutgers Cancer Institute of New Jersey, suggests the day that happens could be getting closer.
› Verified 5 days ago
Nelson Essiet, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 8140 N Mopac Expy Ste 3-210, Austin, TX 78759 Phone: 512-343-2292 | |
Tasha Elleen Seidenberger, AA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 8140 N Mopac Expy, Austin, TX 78759 Phone: 512-343-2292 | |
Jeffrey Allen Rowland, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 8140 N Mopac Expy Ste 3-210, Austin, TX 78759 Phone: 512-493-9237 | |
Alice Lin, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 8140 N Mopac Expy Ste 3-210, Austin, TX 78759 Phone: 512-493-9237 | |
Jialei Xu, Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 919 E 32nd St, Austin, TX 78705 Phone: 512-476-7111 | |
Mrs. Regina D Phillips, A.A. Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 919 E 32nd St, Austin, TX 78705 Phone: 512-476-7111 |